Efficacy of Piperacillin-tazobactam as Empirical Antimicrobial Therapy for VAP Among ESBL-E Carriers.
Status:
Not yet recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
Antimicrobial resistance is a major threat worldwide and now concerns last-ressource
antibiotics such as carbapenems. As the resistance to carbapenems is directly due to their
use, their spare has become a public health emergency. Their efficacy in
ventilator-associated pneumonia has never been compared to other classes of antibiotics such
as piperacillin-tazobactam which can be an alternative to carbapenems.
Phase:
N/A
Details
Lead Sponsor:
University Hospital, Bordeaux
Treatments:
Anti-Bacterial Agents Anti-Infective Agents Piperacillin Piperacillin, Tazobactam Drug Combination Tazobactam